|Last Price||Today's Change||52-Week Range||Trading Volume|
|41.69||0.02 (+0.05%)||19.21 - 46.48||433.9 thousand (Below Avg)|
Market data as of 4:00PM 07/02/15. Quotes are delayed by at least 15 min.
ACADIA Pharmaceuticals Presents Integrated Data from Its Phase III Program with NUPLAZID™ (Pimavanserin) for Parkinson’s Disease Psychosis at the 19th International Congress of Parkinson’s Disease and Movement Disorders
06/16/2015 9:00 AM ET